Completed PHASE3 INTERVENTIONAL 2-arm NCT01516736

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim (PROTECT2)

Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®

Sponsor: Sandoz

Conditions Breast Cancer Chemotherapy-induced Neutropenia

Interventions LA-EP2006 Neulasta®

Updated 8 times since 2017 Last updated: Aug 1, 2017 Started: Mar 31, 2012 Primary completion: Aug 31, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01516736, this PHASE3 trial focuses on Breast Cancer and Chemotherapy-induced Neutropenia and remains completed. Sponsored by Sandoz, it has been updated 8 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Aug 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — Aug 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sandoz
Sandoz GmbH

Data source: Sandoz

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arkhangelsk, Russia , Barcelona, Spain , Bashkortostan, Russia , Bismarck, United States , Bryansk, Russia , Chennai, India , Corona, United States , Delhi, India , Detroit, United States , Eugene, United States and 37 more locations